The Myostatin A2379G Polymorphism and Muscle Strength Among African Americans

Kostek, Matthew C.; Goodspeed, Min K.; Seip, Richard L.; Angelopoulos, Theodore J.; Clarkson, Priscilla M.; Gordon, Paul M.; Moyna, Naill; Visich, Paul S.; Zoeller, Robert F.; Bilbie, Steve; Thompson, Paul D.; Devaney, Joseph M.; Hoffman, Eric P.; Pescatello, Linda S.

doi:10.1249/01.mss.0000274080.01179.90

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the higher tetanic isometric force does not compromise the specific force, 39 which is supported by the heterozygous advantage noted in both dogs and humans. 49,50 Additionally, there is a difference in the fiber length/muscle length ratio for soleus (0.7) and EDL (0.44) muscles, which may also contribute to our findings. Potentially the degree of pennation is not so pronounced for the soleus muscle, whereas the pennation angle may surpass a threshold limit for which EDL function begins to be compromised.…”

Section: Discussionmentioning

confidence: 67%

Adeno-Associated Virus-8-Mediated Intravenous Transfer of Myostatin Propeptide Leads to Systemic Functional Improvements of Slow but Not Fast Muscle

Foster

Graham²,

Otto³

et al. 2009

Rejuvenation Research

View full text Add to dashboard Cite

Myostatin is a member of the transformating growth factor-beta (TGF-beta) superfamily of proteins and is produced almost exclusively in skeletal muscle tissue, where it is secreted and circulates as a serum protein. Myostatin acts as a negative regulator of muscle mass through the canonical SMAD2/3/4 signaling pathway. Naturally occurring myostatin mutants exhibit a 'double muscling' phenotype in which muscle mass is dramatically increased as a result of both hypertrophy and hyperplasia. Myostatin is naturally inhibited by its own propeptide; therefore, we assessed the impact of adeno-associated virus-8 (AAV8) myostatin propeptide vectors when systemically introduced in MF-1 mice. We noted a significant systemic increase in muscle mass in both slow and fast muscle phenotypes, with no evidence of hyperplasia; however, the nuclei-to- cytoplasm ratio in all myofiber types was significantly reduced. An increase in muscle mass in slow (soleus) muscle led to an increase in force output; however, an increase in fast (extensor digitorum longus [EDL]) muscle mass did not increase force output. These results suggest that the use of gene therapeutic regimens of myostatin inhibition for age-related or disease-related muscle loss may have muscle-specific effects.

show abstract

Section: Discussionmentioning

confidence: 67%